Recro Pharma Inc. (NASDAQ:REPH)’s share price gapped up before the market opened on Tuesday . The stock had previously closed at $8.15, but opened at $8.18. Recro Pharma shares last traded at $8.38, with a volume of 28,871 shares trading hands.

A number of equities analysts have recently weighed in on the company. Zacks Investment Research downgraded Recro Pharma from a “buy” rating to a “hold” rating in a research note on Thursday, March 31st. Brean Capital restated a “buy” rating and issued a $28.00 target price on shares of Recro Pharma in a research note on Friday, May 13th. Finally, HC Wainwright restated a “buy” rating on shares of Recro Pharma in a research note on Saturday, May 14th.

The company’s market cap is $78.30 million. The company has a 50 day moving average price of $7.92 and a 200-day moving average price of $7.30.

Recro Pharma (NASDAQ:REPH) last announced its earnings results on Thursday, May 12th. The specialty pharmaceutical company reported ($0.71) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.66) by $0.05. The business had revenue of $17.70 million for the quarter, compared to analyst estimates of $13 million. Equities analysts expect that Recro Pharma Inc. will post ($3.41) earnings per share for the current fiscal year.

In other news, major shareholder Scp Vitalife Partners (Israel) sold 6,260 shares of the stock in a transaction that occurred on Friday, May 20th. The shares were sold at an average price of $6.46, for a total transaction of $40,439.60. Following the sale, the insider now owns 783,642 shares in the company, valued at $5,062,327.32. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, Director Winston J. Churchill sold 58,331 shares of the stock in a transaction that occurred on Friday, May 20th. The shares were sold at an average price of $7.91, for a total transaction of $461,398.21. The disclosure for this sale can be found here.

Recro Pharma, Inc is a clinical-stage specialty pharmaceutical company. The Company is engaged in developing non-opioid therapeutics for the treatment of pain, initially for acute pain following surgery. The Company’s lead product is an intranasal formulation of Dexmedetomidine (Dex). Its product candidates for pain indications include: Dex-IN, Dex-SL and Fadolmidine (Fado).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.